Vigabatrin therapy for infantile epileptic spasms syndrome with periventricular leukomalacia
Brain and Development · 2026-08 · 48 (4) · 104574
DOI: 10.1016/j.braindev.2026.104574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Development, 2026-08. Verfasst von Azusa Oba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Saitama Children's Medical Center, 1-2, Shin-toshin, Chuo-ku, Saitama, Japan; Division of Epilepsy Center, Saitama Children's …. Hauptthemen laut MEDLINE: Vigabatrin, Spasms, Infantile, Anticonvulsants, Leukomalacia, Periventricular. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Infantile epileptic spasm syndrome (IESS) and periventricular leukomalacia (PVL) cause developmental regression and poor neurological outcomes. The primary treatments for IESS include adrenocorticotropin and vigabatrin; however, no study has yet evaluated the efficacy of vigabatrin for patients with both IESS and PVL. Therefore, we investigated the efficacy and safety of vigabatrin in patients with both disorders. METHODS: We retrospectively enrolled patients with IESS and PVL who were treated with vigabatrin. We performed ophthalmological examinations and electroretinography (ERG) before and after vigabatrin. Treatment response was defined as complete cessation of epileptic spasms and no other seizures after 3 months of vigabatrin. We investigated the responses to vigabatrin, doses used, and adverse effects. RESULTS: Seven patients (5 males) with IESS and PVL were treated with vigabatrin. The median age at vigabatrin initiation was 10 (range, 7-25) months. Three of the seven patients (42.8%) showed complete clinical cessation of epileptic spasms after 3 months of vigabatrin. The median duration between vigabatrin initiation and epileptic spasm cessation was 5 (range: 3-61) days. The adverse effects included poor feeding (n = 1) and abnormal ERG findings during vigabatrin therapy (n = 2). These ERG findings normalized after vigabatrin was reduced or stopped. No respiratory failure, increased secretion, or somnolence was observed. CONCLUSION: Vigabatrin was effective for treating 42.8% of our patients with both IESS and PVL. Vigabatrin was well tolerated, with only a mild effect observed in patients with IESS and PVL. Some treatment-related ERG abnormalities were normalized after vigabatrin was reduced or stopped.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Saitama Children's Medical Center, 1-2, Shin-toshin, Chuo-ku, Saitama, Japan; Division of Epilepsy Center, Saitama Children's Medical Center, 1-2, Shin-toshin, Chuo-ku, Saitama, Japan; Department…
- Division of Neurology, Saitama Children's Medical Center, 1-2, Shin-toshin, Chuo-ku, Saitama, Japan; Division of Epilepsy Center, Saitama Children's Medical Center, 1-2, Shin-toshin, Chuo-ku, Saitama, Japan.
- Division of Ophthalmology, Saitama Children's Medical Center, 1-2, Shin-toshin, Chuo-ku, Saitama, Japan.
Zitieren
APA
Oba, A., Matsuura, R., Horita, H., Daida, A., Hirata, Y., Koichihara, R., Hamano, S. I., Kanbe, T., & Kikuchi, K. (2026). Vigabatrin therapy for infantile epileptic spasms syndrome with periventricular leukomalacia. Brain and Development, 48(4), 104574. https://doi.org/10.1016/j.braindev.2026.104574
Vancouver
Oba A, Matsuura R, Horita H, Daida A, Hirata Y, Koichihara R, et al. Vigabatrin therapy for infantile epileptic spasms syndrome with periventricular leukomalacia. Brain and Development. 2026;48(4):104574. doi:10.1016/j.braindev.2026.104574
BibTeX
@article{Oba2026,
author = {Oba, Azusa and Matsuura, Ryuki and Horita, Haruhito and Daida, Atsuro and Hirata, Yuko and Koichihara, Reiko and Hamano, Shin-Ichiro and Kanbe, Tomoka and Kikuchi, Kenjiro},
title = {Vigabatrin therapy for infantile epileptic spasms syndrome with periventricular leukomalacia},
journal = {Brain and Development},
year = {2026},
volume = {48},
number = {4},
pages = {104574},
doi = {10.1016/j.braindev.2026.104574}
}
EUVIMED